An open, phase IV, multicentre study to assess the long-term persistence of antibodies against hepatitis B and the immune response to a hepatitis B vaccine challenge in healthy children 7 to 9 years old, previously vaccinated with 4 doses of GlaxoSmithKline (GSK) Biologicals’ DTPa-HBV-IPV/Hib vaccine or 4 doses of GSK Biologicals’ HBV vaccine, in clinical trials conducted by GSK Biologicals. - DTPa-HBV-IPV-110

GlaxoSmithKline Biologicals0 个研究点目标入组 150 人开始时间: 2006年4月3日最近更新: 2012年3月19日

适应症

试验速览

暂无简介。

•Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol (return for follow-up visits) should be enrolled in the study.
•A male or female aged 7 to 9 years at the time of study entry (from and including the 7th birthday until and including the 9th birthday).
•Written informed consent obtained from the parent or guardian of the subject.
•In addition to the informed consent that will be signed by parents/guardians or legally acceptable representative, informed assent of the subject will be sought for if the subject is judged able to understand (optional).
•Healthy subjects as established by medical history and clinical examination before entering into the study.
•Subjects who have received a total of 4 doses of DTPa-HBV-IPV/Hib vaccine or a total of 4 doses of HBV vaccine (co-administered with DTPa-IPV/Hib vaccine) in the primary studies DTPa-HBV-IPV-039 or DTPa-HBV-IPV-048 and a booster dose of the same vaccines in the booster studies DTPa-HBV-IPV-058 or DTPa-HBV-IPV-059.
•Are the trial subjects under 18? yes
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) no
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).
•Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the challenge dose of HBV vaccine, or planned use during the study period.
•Evidence of previous hepatitis B booster vaccination since administration of the fourth dose of DTPa-HBV-IPV/Hib vaccine or HBV vaccine in the second year of life.
•History of or intercurrent Hepatitis B disease.
•Administration of immunoglobulins and/or any blood products within the three months preceding challenge dose of HBV vaccine or planned administration during the study period.
•Planned administration/administration of a vaccine not foreseen by the study protocol during the period starting from 30 days before challenge dose of HBV vaccine and ending 30 days after.
•Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the challenge dose of HBV vaccine. (For corticosteroids, this will mean prednisone, or equivalent, >= 0.5 mg/kg/day. Inhaled and topical steroids are allowed.)

发起方